Skip to main content
. 2021 May 16;24(4):780–789. doi: 10.1007/s10120-021-01196-3

Fig. 2.

Fig. 2

Management flowchart of T-DXd-induced interstitial lung disease. BNP brain natriuretic peptide; CMV cytomegalovirus; CRP c-reactive protein; CT computed tomography; DLCO diffusing capacity of the lung carbon monoxide; HRCT high resolution computed tomography; ILD interstitial lung disease, KL-6 Krebs von den Lungen-6; LDH lactate dehydrogenase; SP-D pulmonary surfactant protein-D; T-DXd trastuzumab deruxtecan